Research programme: obesity therapeutics - AdipoGenix/Unigen
Latest Information Update: 12 Jan 2011
At a glance
- Originator AdipoGenix; Unigen Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 12 Jan 2011 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 10 Apr 2006 Preclnical studies in Obesity in USA (unspecified route)